Status:
COMPLETED
CT/MR-US Automatic Fusion System in Pre-procedure Planning for Radiofrequency Ablation
Lead Sponsor:
Seoul National University Hospital
Collaborating Sponsors:
Philips Healthcare
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
20-90 years
Phase:
NA
Brief Summary
To prospectively evaluate the technical success rate of real-time computed tomography/CT/magnetic resonance imagingMR and -ultrasound (CT/MRI-US) automatic fusion system and the long-term therapeutic ...
Detailed Description
RFA is one of commonly used local therapies for primary or secondary liver tumors. For successful and safe procedure, safe route of electrode and lesion visibility are essential for RFA, and the condi...
Eligibility Criteria
Inclusion
- Pathologic or typical imaging based diagnosis of HCC
- Multiphase CT or MRI within 3 months ahead of procedure
- No evidence of distant metastasis
- No contraindications for conventional RFA procedure in our institute, which are uncontrolled coagulopathy (international standard ratio ≥ 1.6, or platelet \> 50,000), poor cooperation, unfeasible for sedation, portal vein tumor thrombus, tumor number \>4, largest tumor size \> 5cm, and tumors abutting portal vein or bile ducts bigger than segmental branches.
Exclusion
- Lack of multiphase CT or MRI withing 3 months ahead of procedure
- RFA planned for palliative purpose
- Diagnosed as non-HCC malignancy
- Right hepatectomy state
Key Trial Info
Start Date :
August 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2016
Estimated Enrollment :
139 Patients enrolled
Trial Details
Trial ID
NCT04844112
Start Date
August 1 2015
End Date
November 30 2016
Last Update
April 14 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.